Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

738 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K. Galanis E, et al. Among authors: coffey m. Mol Ther. 2012 Oct;20(10):1998-2003. doi: 10.1038/mt.2012.146. Epub 2012 Aug 7. Mol Ther. 2012. PMID: 22871663 Free PMC article. Clinical Trial.
Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy.
Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, Thompson B, Vile RG, Heinemann L, Pandha HS, Errington F, Melcher AA, Harrington KJ. Twigger K, et al. Among authors: coffey m. Clin Cancer Res. 2008 Feb 1;14(3):912-23. doi: 10.1158/1078-0432.CCR-07-1400. Clin Cancer Res. 2008. PMID: 18245555
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
Forsyth P, Roldán G, George D, Wallace C, Palmer CA, Morris D, Cairncross G, Matthews MV, Markert J, Gillespie Y, Coffey M, Thompson B, Hamilton M. Forsyth P, et al. Among authors: coffey m. Mol Ther. 2008 Mar;16(3):627-32. doi: 10.1038/sj.mt.6300403. Epub 2008 Feb 5. Mol Ther. 2008. PMID: 18253152 Free article. Clinical Trial.
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.
White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, Melcher AA, Pandha HS, Harrington KJ. White CL, et al. Among authors: coffey m. Gene Ther. 2008 Jun;15(12):911-20. doi: 10.1038/gt.2008.21. Epub 2008 Mar 6. Gene Ther. 2008. PMID: 18323793 Clinical Trial.
Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.
Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, Ilett LJ, Prestwich R, Pandha HS, Coffey M, Selby P, Vile R, Harrington KJ, Melcher AA. Errington F, et al. Among authors: coffey m. Gene Ther. 2008 Sep;15(18):1257-70. doi: 10.1038/gt.2008.58. Epub 2008 Apr 10. Gene Ther. 2008. PMID: 18401435 Free PMC article.
738 results